Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 335NCT03966911
• Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 78NCT01328717
• Peripheral Nerve Blocks for Above-the-knee Amputations: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Blocks for Above-the-knee Amputations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03404180).Phase 4Results postedn = 30NCT03404180
• Personalized Vitamin D Supplementation in European and African Americans: Complete Statistical AnalysisIndependent statistical analysis of Personalized Vitamin D Supplementation in European and African Americans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362269).Phase NAResults postedn = 169NCT02362269
• Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 393NCT03398902
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).Phase 1Results postedn = 49NCT03685591
• Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 25NCT03023891
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 17NCT03359850
• Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 40NCT01323140
• Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00711997).Phase 1/2Results postedn = 9NCT00711997
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 99NCT02041195
• Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 19NCT02019667
• Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 286NCT03070782
• Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00588146).Phase 2Results postedn = 10NCT00588146
• Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo: primary…Phase 3Results postedn = 695NCT02229396
• Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 2NCT05543928
• Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).Phase 1Results postedn = 19NCT02047500
• Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).Phase 2Results postedn = 18NCT03023722
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 304NCT01037790
• Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05068752).Phase 2Results postedn = 10NCT05068752
• Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 861NCT00844649
• PHM2Independent statistical analysis of Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 33NCT02438189
• PHT2Independent statistical analysis of Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 259NCT04863872
• Physical Activity and Participation: Complete Statistical AnalysisIndependent statistical analysis of Physical Activity and Participation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02268916).Phase NAResults postedn = 104NCT02268916
• Physical Health in Midlife: Influences of Adversity and Relationships Over Time: Complete Statistical AnalysisIndependent statistical analysis of Physical Health in Midlife: Influences of Adversity and Relationships Over Time: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 210NCT01853332
• Physiological Flow of Liquids Used in Dysphagia Management (Neuro): Complete Statistical AnalysisIndependent statistical analysis of Physiological Flow of Liquids Used in Dysphagia Management (Neuro): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03192358).Phase NAResults postedn = 40NCT03192358
• PICLSIndependent statistical analysis of Pregnancy Intervention With a Closed-Loop System (PICLS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03774186).Phase NAResults postedn = 24NCT03774186
• Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 31NCT00763412
• Pilot Project of Health Promotion for People With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Pilot Project of Health Promotion for People With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970294).Phase NAResults postedn = 11NCT00970294
• Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 16NCT04502212
• Pioglitazone for the Treatment of Bipolar Depression: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone for the Treatment of Bipolar Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01717040).Phase 4Results postedn = 37NCT01717040
• Pioglitazone Special Drug Use Surveillance “Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus”: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 18,223NCT02002975
• Pioglitazone to Treat Fatty Liver in People With HIV Infection: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone to Treat Fatty Liver in People With HIV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00441272).Phase 2Results postedn = 100NCT00441272
• Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 38NCT00300365
• Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone: Complete Statistical AnalysisIndependent statistical analysis of Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 294NCT02098746
• PIONEER 4Independent statistical analysis of Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 711NCT02863419
• PIONEER 6Independent statistical analysis of PIONEER 6, the randomized phase 3 trial of oral semaglutide versus placebo in subjects with type 2 diabetes, including its MACE endpoint, non-inferiority analysis, Cox model, hazard ratio,…Phase 3Results postedn = 3,183NCT02692716
• PIONEER PLUSA detailed statistical analysis of the randomized phase 3 PIONEER PLUS trial comparing three once-daily doses of oral semaglutide in people with type 2 diabetes, including the registered HbA1c endpoint, ANCOVA methodology,…Phase 3Results postedn = 1,606NCT04707469
• PKUIndependent statistical analysis of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 6NCT00986973
• PLANET 1Independent statistical analysis of Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 353NCT00296374
• Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04177810).Phase 2Results postedn = 25NCT04177810
• PLUMIndependent statistical analysis of Post-Prandial Liver Glucose Metabolism in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03041129).Phase NAResults postedn = 19NCT03041129
• PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 37NCT04493619
• POC1Independent statistical analysis of Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 30NCT00511875
• POINTIndependent statistical analysis of Pediatric Oncology Nutrition Intervention Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06175273).Phase 2/3Results postedn = 20NCT06175273
• PolypillIndependent statistical analysis of Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 475NCT00603590
• Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.: Complete Statistical AnalysisIndependent statistical analysis of Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 22NCT02272998
• Portion Control Treatment for Obesity: Complete Statistical AnalysisIndependent statistical analysis of Portion Control Treatment for Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01451554).Phase 2/3Results postedn = 65NCT01451554
• Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner: Complete Statistical AnalysisIndependent statistical analysis of Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 45NCT01114438

← All therapeutic areas